Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Core Insights - Disc Medicine, Inc. is set to present data from its hematology portfolio at the European Hematology Association (EHA) 2024 Congress in Madrid from June 13-16, 2024 [1][2] - The company will showcase four posters highlighting the therapeutic potential of three clinical-stage drugs [2] - Management will conduct a call on June 14, 2024, to review the presented data [2] Presentation Details - Abstract P1575 will present topline results from the AURORA Trial, a Phase 2, randomized, double-blind, placebo-controlled trial of Bitopertin in Erythropoietic Protoporphyria, scheduled for June 14 at 6:00 pm CEST [4] - Abstract P1569 will cover results from the BEACON Trial, also scheduled for June 14 at 6:00 pm CEST [4] - Abstract P1059 will discuss a Phase 1b Trial of DISC-0974 in patients with Myelofibrosis and Anemia, and Abstract P1563 will present a Phase 1 study of DISC-3405 in healthy volunteers, both on June 14 at 6:00 pm CEST [5] Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases [6] - The company aims to build a portfolio of innovative therapeutic candidates targeting red blood cell biology, specifically heme biosynthesis and iron homeostasis [6]